Plot No. 621-P/9, Panoli GIDC, Ankleshwar, Gujarat – 394116 sales@lifechempharma.com+91 98254 40401
blogs

4-Chloro-7H-pyrrolo[2,3-d]pyrimidine: Key Intermediate for Tofacitinib, Ruxolitinib and Baricitinib

By Life Chem Pharma·· 3 min read

4-Chloro-7H-pyrrolo[2,3-d]pyrimidine (CAS 3680-69-1) is the core building block of JAK inhibitors. Uses, specifications and bulk supply from India.

Three of the best-known JAK inhibitors on the market, tofacitinib, ruxolitinib and baricitinib, share the same heterocyclic heart: a 7H-pyrrolo[2,3-d]pyrimidine ring. In almost every commercial route that ring is introduced through one compound, 4-Chloro-7H-pyrrolo[2,3-d]pyrimidine (CAS 3680-69-1). This article explains what the intermediate is, how it is used in JAK inhibitor synthesis, and what to check when you choose a 4-Chloro-7H-pyrrolo[2,3-d]pyrimidine manufacturer for development or commercial supply.

What is 4-Chloro-7H-pyrrolo[2,3-d]pyrimidine?

4-Chloro-7H-pyrrolo[2,3-d]pyrimidine is a fused bicyclic heterocycle, often called a 7-deazapurine, with a reactive chlorine at the 4-position. It is usually made by chlorinating 7H-pyrrolo[2,3-d]pyrimidin-4-ol with phosphorus oxychloride. The chlorine is easily displaced by amines and is a good partner in palladium-catalysed couplings, which is exactly what drug chemists need.

CAS number 3680-69-1
Molecular formula C6H4ClN3
Molecular weight 153.57 g/mol
Appearance Off-white to light beige crystalline powder
Purity (Lifechem) ≥98% (HPLC)

More identifiers, properties and safety data for 4-Chloro-7H-pyrrolo[2,3-d]pyrimidine (CAS 3680-69-1) are listed in the PubChem database.

Why it matters for JAK inhibitors

Janus kinase (JAK) inhibitors treat rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, myelofibrosis and other immune-driven diseases. Their binding to the kinase hinge region depends on the pyrrolo[2,3-d]pyrimidine core, so the 4-chloro compound is the natural starting point.

  • Tofacitinib: the 4-chloro group is displaced (SNAr) by the chiral piperidine amine (3R,4R)-1-benzyl-N,4-dimethylpiperidin-3-amine. After debenzylation and cyanoacetylation the drug substance is obtained.
  • Ruxolitinib: the ring nitrogen is usually protected (for example with SEM or tosyl), and the 4-position is coupled with a pyrazole partner before the chiral cyclopentyl-propanenitrile side chain is completed.
  • Baricitinib: a similar pyrazole coupling at C-4 links the core to the azetidine-acetonitrile part of the molecule.

Because the intermediate is used early in each route, its impurity profile carries through to later steps. A clean, consistent lot saves purification work downstream and keeps regulatory filings simple.

Typical specification buyers ask for

Most procurement and QA teams request the following on the certificate of analysis (COA):

  • Assay by HPLC, typically ≥98%
  • Single largest impurity and total impurities, including the hydroxy precursor 7H-pyrrolo[2,3-d]pyrimidin-4-ol
  • Moisture (Karl Fischer), typically ≤0.5%
  • Residual solvents and phosphorus-containing residues from the chlorination step
  • Identity by IR or 1H NMR

Our current specification is shown on the 4-Chloro-7H-pyrrolo[2,3-d]pyrimidine product page. Tighter limits can be agreed for regulated projects.

Handling, storage and packaging

The compound is a stable solid but should be kept dry, because the C–Cl bond can slowly hydrolyse in the presence of moisture and base. Store it in a cool, dry, well-ventilated area in tightly closed containers. We supply 1 kg, 5 kg and 25 kg fibre drums, and larger lots on request.

Choosing a 4-Chloro-7H-pyrrolo[2,3-d]pyrimidine manufacturer

For a JAK inhibitor programme, price per kilogram is only one part of the decision. Buyers in Europe, the UK and India usually look for:

  1. Consistent quality: the same impurity profile from batch to batch, backed by a COA and retained samples.
  2. Scale: the ability to move from kilograms for development to hundreds of kilograms for validation and launch.
  3. Documentation: SDS, COA, route information and change-control commitments.
  4. Reliable logistics: export-ready packaging and clear lead times.

Lifechem Pharma manufactures advanced intermediates at Panoli GIDC, Ankleshwar, Gujarat, with ISO 9001:2015, ISO 14001:2015 and ISO 45001:2018 certified systems and an in-house QC laboratory. We export to customers in Europe, the UK, Japan and Latin America.

Related products

Teams working on kinase inhibitors often source other pyrimidine building blocks from us as well, such as 2,4-Dichloropyrimidine, 2,4,5-Trichloropyrimidine and 5-Bromo-2,4-dichloropyrimidine. See all advanced intermediates.

Frequently asked questions

What is 4-Chloro-7H-pyrrolo[2,3-d]pyrimidine used for?

It is the key starting material for the pyrrolo[2,3-d]pyrimidine core of JAK inhibitors such as tofacitinib, ruxolitinib and baricitinib, and for many research kinase inhibitors.

What is the CAS number of 4-Chloro-7H-pyrrolo[2,3-d]pyrimidine?

The CAS number is 3680-69-1. The molecular formula is C6H4ClN3 and the molecular weight is 153.57 g/mol.

Is it the same as 4-chloro-7-deazapurine?

Yes. 7-Deazapurine is another name for the pyrrolo[2,3-d]pyrimidine ring system, so both names describe the same compound.

Can you supply samples and a COA?

Yes. We can send a sample with its COA and SDS for evaluation before a commercial order.

Need a quote? Write to Sales@lifechempharma.com with the quantity and destination, or visit the product page.